import { BlogFDACompoundingBan } from "../../../components/blog-fda-compounding-ban.jsx";

export const metadata = {
  title: "FDA Proposes Banning Compounded Semaglutide: What It Means for Your GLP-1 Options in 2026",
  description: "The FDA has proposed banning compounded semaglutide from 503B facilities. Learn what this means for your GLP-1 options and how to navigate the 2026 telehealth landscape safely.",
  openGraph: {
    title: "FDA Proposes Banning Compounded Semaglutide: What It Means for Your GLP-1 Options",
    description: "The FDA has proposed banning compounded semaglutide from 503B facilities. Learn what this means for your GLP-1 options and how to navigate the 2026 telehealth landscape safely.",
    images: [
      {
        url: "https://telehealthfx.com/assets/fda-compounding-ban-featured.png",
        width: 1200,
        height: 630,
        alt: "FDA Compounding Ban",
      },
    ],
  },
};

export default function Page() {
  const jsonLd = {
    "@context": "https://schema.org",
    "@graph": [
      {
        "@type": "Article",
        "@id": "https://telehealthfx.com/blog/fda-compounding-ban/#article",
        "headline": "FDA Proposes Banning Compounded Semaglutide: What It Means for Your GLP-1 Options in 2026",
        "description": "The FDA has proposed banning compounded semaglutide from 503B facilities. Learn what this means for your GLP-1 options and how to navigate the 2026 telehealth landscape safely.",
        "image": "https://telehealthfx.com/assets/fda-compounding-ban-featured.png",
        "author": {
          "@type": "Person",
          "name": "Julian Mercer, M.S.",
          "jobTitle": "Lead Bio-Systems Analyst"
        },
        "publisher": {
          "@type": "Organization",
          "name": "Telehealth FX",
          "logo": {
            "@type": "ImageObject",
            "url": "https://telehealthfx.com/assets/logo.png"
          }
        },
        "mainEntityOfPage": {
          "@type": "WebPage",
          "@id": "https://telehealthfx.com/blog/fda-compounding-ban/"
        }
      },
      {
        "@type": "FAQPage",
        "@id": "https://telehealthfx.com/blog/fda-compounding-ban/#faq",
        "mainEntity": [
          {
            "@type": "Question",
            "name": "Is compounded semaglutide still legal in 2026?",
            "acceptedAnswer": {
              "@type": "Answer",
              "text": "Yes, under certain strict conditions. The FDA's proposal targets 503B outsourcing facilities, preventing them from compounding GLP-1s in bulk. However, 503A traditional compounding pharmacies can still legally prepare patient-specific medications if there is a documented clinical need, such as an allergy to a specific ingredient in the branded product."
            }
          },
          {
            "@type": "Question",
            "name": "What happens if the FDA bans my compounded medication?",
            "acceptedAnswer": {
              "@type": "Answer",
              "text": "If you are currently receiving a compounded GLP-1 from a source that is forced to stop production, you will need to transition to a compliant telehealth provider or obtain a branded prescription (like Wegovy or Zepbound) through your primary care physician. TelehealthFX specializes in guiding patients through compliant, affordable options."
            }
          },
          {
            "@type": "Question",
            "name": "Why is the FDA cracking down on compounding pharmacies?",
            "acceptedAnswer": {
              "@type": "Answer",
              "text": "The FDA is prioritizing patient safety. They found 'no demonstrated clinical need' for bulk compounding of these drugs when FDA-approved versions are available. They also issued warning letters to pharmacies using unsafe ingredients like 'semaglutide sodium' instead of the approved base molecule."
            }
          }
        ]
      }
    ]
  };

  return (
    <>
      <script
        type="application/ld+json"
        dangerouslySetInnerHTML={{ __html: JSON.stringify(jsonLd) }}
      />
      <BlogFDACompoundingBan />
    </>
  );
}
